As filed with the Securities and Exchange Commission on May 11, 2026
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Sana Biotechnology, Inc.
(Exact name of Registrant as specified in its charter)
| Delaware | 83-1381173 | |
| (State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification Number) | |
| 188 East Blaine Street, Suite 350 Seattle, Washington 98102 |
98102 | |
| (Address of Principal Executive Offices) | (Zip Code) | |
2021 Incentive Award Plan
(Full Title of the Plan)
Aaron M. Grossman
Executive Vice President, Chief Legal Officer
Sana Biotechnology, Inc.
188 East Blaine Street, Suite 350
Seattle, Washington 98102
(206) 701-7914
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
Tony Jeffries
Jennifer Knapp
Phillip McGill
Wilson Sonsini Goodrich & Rosati, Professional Corporation
650 Page Mill Road
Palo Alto, CA 94304
(650) 493-9300
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ | |||
| Emerging growth company | ☒ | |||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
EXPLANATORY NOTE
Sana Biotechnology, Inc. (the “Registrant”) is filing this Registration Statement on Form S-8 (this “Registration Statement”) for the purpose of registering an additional 13,336,582 shares of common stock under the Registrant’s 2021 Incentive Award Plan, as amended (the “2021 Plan”), for which registration statements of the Registrant on Form S-8 (File Nos. 333-287088, 333-279219, 333-271728, 333-264846, and 333-252862) are effective (the “Prior Registration Statements”), pursuant to the provisions of the 2021 Plan that provide for an automatic annual increase in the number of shares of common stock reserved for issuance thereunder. This Registration Statement relates to securities of the same class as those to which the Prior Registration Statements relate and is submitted in accordance with General Instruction E to Form S-8 regarding Registration of Additional Securities. Pursuant to General Instruction E to Form S-8, the contents of the Prior Registration Statements are incorporated herein by reference and made part of this Registration Statement, except as amended hereby.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
| Item 3. | Incorporation of Documents by Reference. |
The Registrant hereby incorporates by reference into this Registration Statement the following documents filed by it with the Securities and Exchange Commission (the “SEC”):
| (a) | the Registrant’s Annual Report on Form 10-K (File No. 001-39941) for the fiscal year ended December 31, 2025, filed with the SEC on March 3, 2026 (the “Annual Report”); |
| (b) | all other reports filed pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), since the end of the fiscal year covered by the Annual Report (other than the portions of these documents not deemed to be filed); and |
| (c) | the description of the Registrant’s common stock contained in the Registrant’s Registration Statement on Form 8-A (File No. 001-39941) filed with the Commission on January 25, 2021, pursuant to Section 12(b) of the Exchange Act, as updated and superseded by the description of the Registrant’s common stock contained in Exhibit 4.3 to the Annual Report, including any amendments or reports filed for the purpose of updating such description. |
All documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14, or 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such Current Report that relate to such items) subsequent to the filing of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents; provided, however, that documents or information deemed to have been furnished and not filed in accordance with the rules of the SEC shall not be deemed incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
| Item 8. | Exhibits. |
The exhibits to this Registration Statement are listed below and are incorporated herein by reference.
EXHIBIT INDEX
| * | Filed herewith. |
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Seattle, State of Washington, on May 11, 2026.
| SANA BIOTECHNOLOGY, INC. | ||
| By: |
/s/ Steven D. Harr, M.D. | |
| Steven D. Harr, M.D. | ||
| President and Chief Executive Officer | ||
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Steven D. Harr, M.D. and Brian Piper, and each of them, his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place, and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement and any and all additional registration statements pursuant to Rule 462(b) of the Securities Act of 1933, as amended, and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission, granting unto each said attorney-in-fact and agents full power and authority to do and perform each and every act in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or either of them or their or his or her substitute or substitutes may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.
| Signature | Title | Date | ||
| /s/ Steven D. Harr, M.D. Steven D. Harr, M.D. |
President, Chief Executive Officer, and Director (Principal Executive Officer) | May 11, 2026 | ||
| /s/ Brian Piper Brian Piper |
Executive Vice President, Chief Financial Officer (Principal Financial Officer) | May 11, 2026 | ||
| /s/ Susan D. Wyrick Susan D. Wyrick |
Senior Vice President, Finance and Accounting (Principal Accounting Officer) | May 11, 2026 | ||
| /s/ Hans E. Bishop Hans E. Bishop |
Chairman of the Board | May 11, 2026 | ||
| /s/ Joshua H. Bilenker, M.D. Joshua H. Bilenker, M.D. |
Director | May 11, 2026 | ||
| /s/ Richard Mulligan, Ph.D. Richard Mulligan, Ph.D. |
Director | May 11, 2026 | ||
| /s/ Robert Nelsen Robert Nelsen |
Director | May 11, 2026 | ||
| /s/ Alise S. Reicin, M.D. Alise S. Reicin, M.D. |
Director | May 11, 2026 | ||
| /s/ Robert L. Rosiello Robert L. Rosiello |
Director | May 11, 2026 | ||
| /s/ Michelle Seitz, CFA Michelle Seitz |
Director | May 11, 2026 | ||
| /s/ Patrick Y. Yang, Ph.D. Patrick Y. Yang, Ph.D. |
Director | May 11, 2026 | ||